Development and pharmacokinetic evaluation of a curcumin co-solvent formulation

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4285-4292

  John, Mathew K ^a   Huan, X I E ^a   Bell, Edward C ^a   Liang, Dong ^a  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

Curcumin formulation; Intramuscular; Pharmacokinetics

Indexed keywords

COSOLVENT; CURCUMIN; SOLVENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG LIQUID FORMULATION; DRUG SOLUBILITY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE;

CURCUMIN FORMULATION; INTRAMUSCULAR; PHARMACOKINETICS;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; ETHANOL; INJECTIONS, INTRAMUSCULAR; MALE; POLYETHYLENE GLYCOLS; POLYSORBATES; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SOLVENTS;

EID: 84891369406     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Aggarwal BB, Sundaram C, Malani N et al: Curcumin the Indian solid gold. Adv Exp Med Biol 595: 1-75, 2007.
2. Shukla PK, Khanna VK, Khan MY et al: Protective effect of curcumin against lead neurotoxicity in rat. Hum Exp Toxicol 22: 653-658, 2003.
3. Abe Y, Hashimoto S and Horie T: Curcumin inhibition of inflammatory cytokine production by human peripheralblood monocytes and alveolar macrophages. Pharmacol Res 39: 41-47, 1999.
4. Pari L and Murugan P: Antihyperlipidemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic rats. Ren Fail 29: 881-889, 2007.
5. Aggarwal BB, Kumar A and Bharthi AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23: 363-398, 2003.
6. Liu D, Schwimer J, Liu Z et al: Anti-angiogenic effect of curcumin in pure versus in extract forms. Pharm Biol 46: 677-682, 2008.
7. Shankar TN, Shantha NV, Ramesh HP et al: Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guinea pigs and monkeys. Indian J Exp Biol 18: 73-75, 1980.
8. Qureshi S, Shah AH and Ageel AM: Toxicity studies on Alpiniagalanga and Curcuma longa. Planta Med 58: 124-127, 1992.
9. Lao CD, Demierre MF and Sondak VK: Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert Rev Anti-cancer Ther 6: 1559-1568, 2006.
10. Lao CD, Ruffin MT, Normolle D et al: Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6: 10, 2006.
11. Cheng AL, Hsu CH, Lin JK et al: Phase I clinical trial of curcumin, a chemo preventive agent in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900, 2001.
12. Wahlang B, Pawar YB and Bansal AK: Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. Euro J Pharm Biopharm 77: 275-282, 2011.
13. Tonnesen HH: Solubility, chemical and photochemical stability of curcumin in surfactant solutions. Studies of curcumin and curcuminoids XXVII. Pharmazie 57: 820-824, 2002.
14. Tonnesen HH, Masson M and Loftsson T: Studies of curcumin and curcuminoids XXVII. Cyclodextrin complexation: Solubility, chemical and photochemical stability. Int J Pharm 244: 127-135, 2002.
15. Yang KY, Lin LC, Tseng TU et al: Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 853: 183-189, 2007.
16. Shoba G, Joy D, Joseph T et al: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356, 1998.
17. Onoue S, Takahashi H, Kawabata Y et al: Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J Pharm Sci 99: 1871-1881, 2010.
18. Seo SW, Han HK, Chun MK et al: Preparation and pharmacokinetic evaluation of curcumin solid dispersion using Solutol® HS15 as a carrier. Int J Pharm 424: 18-25, 2012.
19. Vasconcelos T, Sarmento B and Costa P: Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 12: 1068-1075, 2007.
20. Takahashi M, Uechi S, Takara K et al: Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. J Agric Food Chem 57: 9141-9146, 2009.
21. Mohanty C and Sahoo SK: The in vitro stability and in-vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Bio-materials 25: 6597-6611, 2010.
22. Anand P, Kunnumakkara AB, Newman RA et al: Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807-818, 2007.
23. Bansal SS, Goel M, Aqil F et al: Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (phila) 4: 1158-1171, 2011.
24. Savjani KT, Gajjar AK and Savjani JK: Drug solubility: Importance and enhancement techniques. ISRN Pharm 195727, 2012.
25. RabinowBE: Nanosuspensions in drug delivery. Nat Rev Drug Discov 3: 785-796, 2004.
26. Salem HF: Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized rats. Int J Nanomedicine 5: 943-954, 2010.
27. Rhee YS, Sohn M, Woo BH et al: Sustained-release delivery of octreotide from biodegradable polymeric microspheres. AAPSPharmSciTech 4: 1293-1301, 2011.
28. Ahmed TA, Ibrahim HM, Ibrahim F et al: Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol. J Pharm Sci 101: 3753-3762, 2012.
29. Xiong MP, Yariez JA, Remsberg CM et al: Formulation of a geldanamycinprodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats. J Control Release 129: 33-40, 2008.
30. Liu A, Lou H, Zhao L et al: Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J Pharm Biomed Anal 40: 720-727, 2006.
31. Shaikh J, Ankola DD, Beniwal V et al: Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37: 223-230, 2009.
32. Anand P, Nair HB, Sung B et al: Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in-vivo Biochem Pharmacol 79: 330-338, 2010.
33. Mohanty C and Sahoo SK: The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Bio-materials 25: 6597-6611, 2010.
34. Walters MC and Furyk J: Paediatric Intramuscular Injections for Developing World Settings: A Review of the Literature for Best Practices. J Transcult Nurs 23: 406-409, 2012.
35. Wei XL, Han YR, Quan LH et al: Oily nanosuspension for long-acting intramuscular delivery of curcumin didecanoate prodrug: Preparation characterization and in vivo evaluation. Eur J Pharm Sci 49: 286-293, 2013.
36. Strickley RG: Solubilizing excipients in oral and injectable formulations. Pharm Res 21: 201-300, 2004.
37. Avdeef A: Solubility of sparingly-soluble ionizable drugs. Adv Drug Deliv Rev 59: 568-590, 2007.
38. Chow ST and Ng TL: The biodegradation of N-methyl-2-pyrrolidone in water by sewage bacteria. Water Res 17: 117-118, 1983.
39. Jouyban A, Fakhree MA and Shayanfar A: Review of pharmaceutical applications of N-methyl-2-pyrrolidone. J Pharm Pharm Sci 13: 524-535, 2010.
40. Singh R and Lillard JW Jr.: Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86: 215-223, 2009.